H.R. 4553 — Introduced in House

I 116th CONGRESS 1st Session H. R. 4553 IN THE HOUSE OF REPRESENTATIVES September 27, 2019Mr. Brendan F. Boyle of Pennsylvania (for himself, Mr. Marshall, Mr. Veasey, and Mr. Fortenberry) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To expand the tropical disease product priority review voucher program to encourage treatments for the Middle East respiratory syndrome, Nipah, and Rift Valley fever. 1. Short title This Act may be cited as the Adding Epidemic Diseases to the FDA Priority Review Voucher Program Act. 2. Expanding tropical disease product priority review voucher program to encourage treatments for Middle East respiratory syndrome, Nipah, and Rift Valley fever Section 524(a)(3) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360n(a)(3)) is amended— (1) by redesignating subparagraph (S) as subparagraph (V); and (2) by inserting after subparagraph (R) the following: (S) Middle East respiratory syndrome. (T) Nipah. (U) Rift Valley fever. .